An evaluation of the pharmacokinetics of methylphenidate for the treatment of attention-deficit/ hyperactivity disorder

Bibliography

• Wolraich MI, McGuin I, Dofting M. Treatment of attention deficit hyperactivity disorder in children and adolescents: safety considerations. Drug Saf 2007;30(1):17-26
   PubMed Web of Science ®Google Scholar
• AACAP. Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder. American Academy of Child and Adolescent Psychiatry, Washington, DC, 2007
   Google Scholar
• National Collaborating Centre for Mental Health (UK). Attention deficit hyperactivity disorder: diagnosis and management of ADHD in children, young people and adults. British Psychological Society; Leicester, UK: 2009. NICE Clinical Guidelines, No. 72 Available from: http://www.ncbi.nlm.nih.gov/books/NBK53652/2009
   Google Scholar
• Banaschewski T, Coghill D, Santosh P, et al. Long acting medications for the hyperkinetic disorders. A systematic review and European treatment guideline. Eur Child Adolesc Psychiatry 2006;15(8):476-95
   PubMed Web of Science ®Google Scholar
• Hardy SE. Methylphenidate for treatment of depressive symptoms, apathy, and fatigue in medically ill older adults and terminally ill adults. Am J Geriatr Pharmacother 2009;7(1):34-59
   PubMed Web of Science ®Google Scholar
• Prommer E. Methylphenidate: established and expanding roles in symptom management. Am J Hosp Palliat care 2012;29(6):483-90
   PubMed Web of Science ®Google Scholar
• Volkow ND, Fowler JS, Wang GJ, et al. Mechanism of action of methylphenidate: insights from PET imaging studies. J Atten Disord 2002;6(Suppl 1):31-43
   PubMedGoogle Scholar
• Dougherty DD, Bonab AA, Spencer TJ, et al. Dopamine transporter density in patients with attention deficit hyperactivity disorder. Lancet 1999;354:2132-3
   PubMed Web of Science ®Google Scholar
• Vles JS, Feron FJ, Hendriksen JG, et al. Methylphenidate down-regulates the dopamine receptor and transporter system in children with attention deficit hyperkinetic disorder (ADHD). Neuropediatrics 2003;34:77-80
   PubMed Web of Science ®Google Scholar
• Seeman P, Madras BK. Anti-hyperactivity medication: methylphenidate and amphetamine. Mol Psychiatry 1998;3:386-96
   PubMed Web of Science ®Google Scholar
• Volkow ND, Wang G, Fowler JS, et al. Therapeutic doses of oral methylphenidate significantly increase extracellular dopamine in the human brain. J Neurosci 2001;21:RC121
   PubMed Web of Science ®Google Scholar
• Köhler C, Hall H, Ogren SO, Gawell L. Specific in vitro and in vivo binding of 3H-raclopride. A potent substituted benzamide drug with high affinity for dopamine D-2 receptors in the rat brain. Biochem Pharmacol 1985;34(13):2251-9
   PubMed Web of Science ®Google Scholar
• Krause KH, Dresel SH, Krause J, et al. Increased striatal dopamine transporter in adult patients with attention deficit hyperactivity disorder: effects of methylphenidate as measured by single photon emission computed tomography. Neurosci Lett 2000;285(2):107-10
   PubMed Web of Science ®Google Scholar
• Dafny N, Yang PB. The role of age, genotype, sex, and route of acute and chronic administration of methylphenidate: a review of its locomotor effects. Brain Res Bull 2006;68(6):393-405
   PubMed Web of Science ®Google Scholar
• Volkow ND, Swanson JM. Variables that affect the clinical use and abuse of methylphenidate in the treatment of ADHD. Am J Psychiatry 2003;160(11):1909-18
   PubMed Web of Science ®Google Scholar
• Volkow ND, Fowler JS, Wang GJ, et al. Role of dopamine in the therapeutic and reinforcing effects of methylphenidate in humans: results from imaging studies. Eur Neuropsychopharmacol 2002;12:557-66
   PubMed Web of Science ®Google Scholar
• Volkow ND, Wang GJ, Fowler JS, et al. Relationship between blockade of dopamine transporters by oral methylphenidate and the increases in extracellular dopamine: therapeutic implications. Synapse 2002;43:181-7
   PubMed Web of Science ®Google Scholar
• Krause J, la Fougere C, Krause KH, et al. Influence of striatal dopamine transporter availability on the response to methylphenidate in adult patients with ADHD. Eur Arch Psychiatry Clin Neurosci 2005;428-31
   PubMed Web of Science ®Google Scholar
• Volkow ND, Wang GJ, Fowler JS, Ding Y. Imaging the effects of methyphenidate on brain dopamine: new model on its therapeutic actions for attention-deficit/hyperactivity disorder. Biol Psychiatry 2005;57:1410-15
   PubMed Web of Science ®Google Scholar
• Arnsten A. Toward a new understanding of attention-deficit hyperactivity disorder pathophysiology: an important role for prefrontal cortex dysfunction. CNS Drugs 2009;23(Suppl 1):33-41
   PubMed Web of Science ®Google Scholar
• Floresco SB. Prefrontal dopamine and behavioral flexibility: shifting from an “inverted-U” toward a family of functions. Front Neurosci 2013;19:7-62
   Google Scholar
• Gustafsson P, Themlund G, Ryding E, et al. Associations between cerebral blood-flow measured by single photon computed tomography (SPECT), electro-encephalogram (EEG), behaviour symptoms, cognition and neurological soft signs in children with attention-deficit hyperactivity disorder (ADHD). Acta Paediatr 2000;89(7):830-5
   PubMed Web of Science ®Google Scholar
• Kim BN, Lee JS, Cho SC, Lee DS. Methylphenidate increases regional cerebral blood flow in subjects with attention-deficit hyperactivity disorder. Yonsei Med J 2001;42(1):19-29
   PubMed Web of Science ®Google Scholar
• Wilens TE. Effects of methylphenidate on the catecholaminergic system in attention-deficit/hyperactivity disorder. J Clin Psychopharmacol 2008;28(3):46-53
   Google Scholar
• Unis AS, Dawson TM, Gehlert DR, Wamsley JK. Autoradiographic localization of [3H]methylphenidate binding sites in rat brain. Eur J Pharmacol 1985;13:155-7
   Google Scholar
• Arakawa R, Okumura M, Ito H, et al. Quantitative analysis of norepinephrine transporter in the human brain using PET with (S,S)-18F-FMeNER-D2. J Nucl Med 2008;49(8):1270-6
   PubMed Web of Science ®Google Scholar
• Kim CH, Hahn MK, Joung Y, et al. A polymorphism in the norepinephrine transporter gene alters promoter activity and is associated with attention-deficit hyperactivity disorder. Proc Natl Acad Sci USA 2006;103:19164-9
   PubMed Web of Science ®Google Scholar
• Hannestad J, Gallezot JD, Planeta-Wilson B, et al. Clinically relevant doses of methylphenidate significantly occupy norepinephrine transporters in humans in vivo. Biol Psychiatry 2010;68:854-60
   PubMed Web of Science ®Google Scholar
• Madras BK, Miller GM, Fischman AJ. The dopamine transporter and attention-deficit/hyperactivity disorder. Biol Psychiatry 2005;57(11):1397-409
   PubMed Web of Science ®Google Scholar
• Balcioglu A, Ren JQ, McCarthy D, et al. Plasma and brain concentrations of oral therapeutic doses of methylphenidate and their impact on brain monoamine content in mice. Neuropharmacology 2009;57:687-93
   PubMed Web of Science ®Google Scholar
• Moron JA, Brockington A, Wise RA, et al. Dopamine uptake through the norepinephrine transporter in brain regions with low levels of the dopamine transporter: evidence from knock-out mouse lines. J Neurosci 2002;22:389-95
   PubMed Web of Science ®Google Scholar
• Yamamoto BK, Novotney S. Regulation of extracellular dopamine by the norepinephrine transporter. J Neurochem 1998;71:274-80
   PubMed Web of Science ®Google Scholar
• Ishimatsu M, Kidani Y, Tsuda A, Akasu T. Effects of methylphenidate on the membrane potential and current in neurons of the rat locus coeruleus. J Neurophysiol 2002;87:1206-12
   PubMed Web of Science ®Google Scholar
• Leonard BE, McCartan D, White J, King DJ. Methylphenidate: a review of its neuropharmacological, neuropsychological and adverse clinical effects. Hum Psychopharmacol 2004;19:151-80
   PubMed Web of Science ®Google Scholar
• Kiyatkin EA. Dopamine in the nucleus accumbens: cellular actions, drug- and behavior-associated fluctuations, and a possible role in an organism’s adaptive activity. Behav Brain Res 2002;137:27-46
   PubMed Web of Science ®Google Scholar
• Keeler JD, Pichler EE, Ross J. Noise in neural networks: thresholds, hysteresis, and neuromodulation of signal-to-noise. Proc Natl Acad Sci USA 1989;86:1712-16
   PubMed Web of Science ®Google Scholar
• Rolls T, Thorpe SJ, Boytim M, et al. Responses of striatal neurons in the behaving monkey. 3. Effects of iontophoretically applied dopamine on normal responsiveness. Neuroscience 1984;12:1201-12
   PubMed Web of Science ®Google Scholar
• Cepeda C, Buchwald NA, Levine MS. Neuromodulatory actions of dopamine in the neostriatum are dependent upon the excitatory amino acid receptor subtypes activated. Proc Natl Acad Sci USA 1993;90(20):9576-80
   PubMed Web of Science ®Google Scholar
• Volkow ND, Fowler JS, Wang GJ, et al. Methylphenidate decreased the amount of glucose needed by the brain to perform a cognitive task. PLoS One 2008;3(4):e2017
   PubMed Web of Science ®Google Scholar
• Markowitz JS, Straughn AB, Patrick KS. Advances in the pharmacotherapy of attention-deficit/hyperactivity disorder: focus on methylphenidate formulations. Pharmacotherapy 2003;23(10):1281-99
   PubMed Web of Science ®Google Scholar
• Sun Z, Murry DJ, Sanghani SP, et al. Methylphenidate is stereoselectively hydrolyzed by human carboxylesterase CES1A1. J Pharmacol Exp Ther 2004;310(2):469-76
   PubMed Web of Science ®Google Scholar
• Zhu HJ, Appel DI, Peterson YK, et al. Identification of selected therapeutic agents as inhibitors of carboxylesterase 1: potential sources of metabolic drug interactions. Toxicology 2010;270(2-3):59-65
   PubMed Web of Science ®Google Scholar
• Aoyama T, Kotaki H, Sasaki T, et al. Pharmacokinetics and pharmacodynamics of (+)-threo-methylphenidate enantiomer in patients with hy-persomnia. Clin Pharmacol Ther 1994;55:270-6
   PubMed Web of Science ®Google Scholar
• Wargin W, Patrick K, Kilts C, et al. Pharmacokinetics of methylphenidate in man, rat and monkey. J Pharmacol Exp Ther 1983;226:382-6
   PubMed Web of Science ®Google Scholar
• Patrick KS, Kilts CD, Breese GR. Synthesis and pharmacology of hydroxylated metabolites of methylphenidate. J Med Chem 1981;24:1237-40
   PubMed Web of Science ®Google Scholar
• Novartis Pharmaceuticals Corp. East Hanover, NJ: Ritalin® prescribing information 2007
   Google Scholar
• Heal DJ, Smith SL, Kulkarni RS, Rowley HL. New perspectives from microdialysis studies in freelymoving, sponaneously hypertensive rats on the pharmacology of drugs for the treatment of ADHD. Pharmacol Biochem Behav 2008;90:184-97
   PubMed Web of Science ®Google Scholar
• Jones SR, Gainetdinov RR, Wightman RM, Caron MG. Mechanisms of amphetamine action revealed in mice lacking the dopamine transporter. J Neurosci 1998;18:1979-86
   PubMed Web of Science ®Google Scholar
• Ding YS, Fowler JS, Volkow ND, et al. Carbon-ll-d-threo-methylphenidate binding to dopamine transporter in baboon brain. J Nucl Med 1995;36:2298-305
   PubMed Web of Science ®Google Scholar
• Ding YS, Fowler JS, Volkow ND, et al. Chiral drugs: comparison of the pharmacokinetics of [11C]d-threo and l-threo-methylphenidate in the human and baboon brain. Psychopharmacology (Berl) 1997;131:71-8
   PubMed Web of Science ®Google Scholar
• Teo SK, Stirling DI, Thomas SD, Khetani VD. Neurobehavioral effects of racemic threo-methylphenidate and its D and L enantiomers in rats. Pharmacol Biochem Behav 2003;74:747-54
   PubMed Web of Science ®Google Scholar
• Davids E, Zhang K, Tarazi FI, Baldessarini RJ. Stereoselective effects of methylphenidate on motor hyperactivity in juvenile rats induced by neonatal 6-hydroxydopamine lesioning. Psychopharmacology (Berl) 2002;160:92-8
   PubMed Web of Science ®Google Scholar
• Quinn D. Does Chirality Matter? Pharmacodynamics of enantiomers of methylphenidate in patients with Attention-Deficit/Hyperactivity Disorder. J Clin Psychopharmacol 2008;28(3):62-6
   Google Scholar
• Wigal SB, Gupta S, Greenhill I, et al. Pharmacokinetics of methylphenidate in preschoolers with Attention-Deficit/Hyperactivity Disorder. J Child Adolesc Psychopharmacol 2007;17:153-64
   PubMed Web of Science ®Google Scholar
• Volkow ND, Wang GJ, Fowler JS, et al. Dopamine transporter occupancies in the human brain induced by therapeutic doses of oral methylphenidate. Am J Psychiatry 1998;155:1325-31
   PubMed Web of Science ®Google Scholar
• Kollins SH. Comparing the abuse potential of methylphenidate versus other stimulants: a review of available evidence and relevance to the ADHD patient. J Clin Psychiatr 2003;64:14-18
   PubMed Web of Science ®Google Scholar
• Chan YP, Swanson JM, Soldin SS, et al. Methylphenidate hydrochloride given with or before breakfast: II. Effects on plasma concentration of methylphenidate and ritalinic acid. Pediatrics 1983;72:56-9
   PubMed Web of Science ®Google Scholar
• Volkow N, Ding YS, Fowler JS, et al. Is methylphenidate like cocaine? Studies on their pharmacokinetics and distribution in the human brain. Arch Gen Psychiatry 1995;52(6):456-63
   PubMed Web of Science ®Google Scholar
• Spencer TJ, Biederman J, Ciccone PE, et al. PET study examining pharmacokinetics, detection and likability, and dopamine transporter receptor occupancy of short-and long-acting oral methylphenidate. Am J Psychiatry 2006;163:387-95
   PubMed Web of Science ®Google Scholar
• Wang GJ, Volkow ND, Hitzemann RJ, et al. Behavioral and cardiovascular effects of intravenous methylphenidate in normal subjects and cocaine abusers. Eur Addict Res 1997;41:49-54
   Web of Science ®Google Scholar
• Gatley SJ, Volkow ND, Gifford AN, et al. Dopamine-transporter occupancy after intravenous doses of cocaine and methylphenidate in mice and humans. Psychopharmacology (Berl) 1999;146:93-100
   PubMed Web of Science ®Google Scholar
• Parran TV, Jasinski DR. Intravenous methylphenidate abuse: prototype for prescription drug abuse. Arch Intern Med 1991;151:781-3
   PubMed Web of Science ®Google Scholar
• Faraj BA, Israili AH, Perel JM, et al. Metabolism and disposition of methylphenidate14C: studies in man and animals. J Pharmacol Exp Ther 1974;191:535-47
   PubMed Web of Science ®Google Scholar
• Stoops WW, Glaser PE, Fillmore MT, Rush CR. Reinforcing, subject-rated, performance and physiological effects of methylphenidate and d-amphetamine in stimulant abusing humans. J Psychopharmacol 2004;18(4):534-43
   PubMed Web of Science ®Google Scholar
• Gahr M, Freudenmann RW, Hiemke C, et al. Abuse of methylphenidate in Germany: data from spontaneous reports of adverse drug reactions. Psychiatry Res 2014;215(1):252-4
   PubMed Web of Science ®Google Scholar
• Levin FR, Kleber HD. Attention-devicit hyperactivity disorder and substance abuse: relationships and implications for treatment. Harvard Rev Psychiatry 1995;2:246-58
   PubMed Web of Science ®Google Scholar
• Mozley LH, Gur RC, Mozley PD, Gur RE. Striatal dopamine transporters and cognitive functioning in healthy men and women. Am J Psychiatry 2001;158(9):1492-9
   PubMed Web of Science ®Google Scholar
• Bhatt SD, Dluzen DE. Dopamine transporter function differences between male and female CD-1 mice. Brain Res 2005;1035(2):188-95
   PubMed Web of Science ®Google Scholar
• Lavalaye J, Booij J, Reneman L, et al. Effect of age and gender on dopamine transporter imaging with [I-123]FP-CIT SPET in healthy volunteers. Eur J Nucl Med 2000;27(7):867-9
   PubMedGoogle Scholar
• Anderson VR, Keating GM. Methylphenidate controlled-delivery capsules (EquasymXL, Metadate CD): a review of its use in the treatment of children and adolescents with attention-deficit hyperactivity disorder. Paediatr Drugs 2006;8(5):319-33
   PubMedGoogle Scholar
• Patrick KS, Straughn AB, Minhinnett RR, et al. Influence of ethanol and gender on methylphenidate pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther 2007;81(3):346-53
   PubMed Web of Science ®Google Scholar
• Markowitz JS, Straughn AB, Patrick KS. Advances in the pharmacotherapy of attention-deficit-hyperactivity disorder: focus on methylphenidate formulations. Pharmacotherapy 2003;23(10):1281-99
   PubMed Web of Science ®Google Scholar
• Cornforth C, Sonuga-Barke E, Coghill D. Stimulant drug effects on attention deficit/hyperactivity disorder: a review of the effects of age and sex of patients. Curr Pharm Des 2010;16(22):2424-33
   PubMed Web of Science ®Google Scholar
• Greenhill L, Kollins S, Abikoff H, et al. Efficacy and safety of immediate-release methylphenidate treatment for preschoolers with ADHD. J Am Acad Child Adolesc Psychiatry 2006;45(11):1284-93
   PubMed Web of Science ®Google Scholar
• Wong J, Asherson P, Bilbow A, et al. Cessation of attention deficit hyperactivity disorder drugs in the young (CADDY) – a pharmacoepidemiological and qualitative study. Health Technol Assess 2009;13(50):1-144
   Web of Science ®Google Scholar
• Biederman J, Faraone S, Mick E, Lelon E. Psychiatric comorbidity among referred juveniles with major depression – fact or artifact. J Am Acad Child Adolesc Psychiatry 1995;34(5):579-90
   PubMed Web of Science ®Google Scholar
• Wilens T, Gignac M, Swezey A, et al. Characteristics of adolescents and young adults with ADHD who divert or misuse their prescribed medications. J Am Acad Child Adolesc Psychiatry 2006;45(4):408-14
   PubMed Web of Science ®Google Scholar
• Smith BH, Waschbusch DA, Willoughby MT, Evans S. The efficacy, safety, and pracitcality of treatments for adolescents with attention-deficit/hyperactivity disorder (ADHD). Clin Child Fam Psychol Rev 2000;3(4):243-67
   PubMedGoogle Scholar
• Kooij JJS, Burger H, Boonstra AM, et al. Efficacy and safety of methylphenidate in 45 adults with attention-deficit/hyperactivity disorder. A randomized placebo-controlled double-blind cross-over trial. Psychol Med 2004;34(6):973-82
   PubMed Web of Science ®Google Scholar
• Spencer T, Biederman J, Wilens T, et al. A large, double-blind, randomized clinical trial of methylphenidate in the treatment of adults with attention-deficit/hyperactivity disorder. Biol Psychiatry 2005;57(5):456-63
   PubMed Web of Science ®Google Scholar
• Faraone SV, Spencer T, Aleardi M, et al. Meta-analysis of the efficacy of methylphenidate for treating adult attention-deficit/hyperactivity disorder. J Clin Psychopharmacol 2004;24:24-9
   PubMed Web of Science ®Google Scholar
• Buitelaar JK, Ramos-Quiroga JA, Casas M, et al. Safety and tolerability of flexible dosages of prolonged-release OROS methylphenidate in adults with attention-deficit/hyperactivity disorder. Neuropsychiatr Dis Treat 2009;5:457-66
   PubMed Web of Science ®Google Scholar
• Taylor E, Schachar R, Thorley G, et al. Which boys respond to stimulant medication? A controlled trial of methylphenidate in boys with disruptive behaviour. Psychol Med 1987;17(1):121-43
   PubMed Web of Science ®Google Scholar
• Buitelaar JK, Van der Gaag RJ, Swaab-Barneveld H, Kuiper M. Prediction of clinical response to methylphenidate in children with attention deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2005;34(8):1025-32
   Google Scholar
• Faraone SV, Buitelaar J. Comparing the efficacy of stimulants for ADHD in children and adolescents using meta-analysis. Eur J Child Adolesc Psychiatry 2009;8(4):4
   Google Scholar
• MTA Cooperative Group. A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. Arch Gen Psychiatry 1999;56:1073-86
   PubMed Web of Science ®Google Scholar
• MTA Cooperative Group. Moderators and mediators of treatment response for children with attention-deficit/hyperactivity disorder. Arch Gen Psychiatry 1999;56:1088-96
   PubMed Web of Science ®Google Scholar
• Pliszka SR. Pharmacologic treatment of attention-deficit/hyperactivity disorder: efficacy, safety and mechanisms of action. Neuropsychol Rev 2007;17:61-72
   PubMed Web of Science ®Google Scholar
• Coghill DR, Rhodes SM, Matthews K. The neuropsychological effects of chronic methylphenidate on drug-naive boys with attention-deficit/hyperactivity disorder. Biol Psychiatry 2007;62(9):954-62
   PubMed Web of Science ®Google Scholar
• Rapport MD, Denney C, DuPaul GJ, Gardner MJ. Attention deficit disorder and methylphenidate: normalization rates, clinical effectiveness, and response prediction in 76 children. J Am Acad Child Adolesc Psychiatry 1994;33:882-93
   PubMed Web of Science ®Google Scholar
• Schachter HM, Pham B, King J, et al. How efficacious and safe is short-acting methylphenidate for the treatment of attention-deficit disorder in children and adolescents? A meta-analysis. CMAJ 2001;165(11):1475-88
   PubMed Web of Science ®Google Scholar
• Klein RG, Abikoff H, Klass E, et al. Clinical efficacy of methylphenidate in conduct disorder with and without attention deficit hyperactivity disorder. Arch Gen Psychiatry 1997;54(12):1073-80
   PubMed Web of Science ®Google Scholar
• Balthazor MJ, Wagner RK, Pelham WE. The specificity of the effects of stimulant medication on classroom-learning related measures of cognitive processing for attention deficit disorder children. J Abnorm Child Psychol 1991;19:35-52
   PubMed Web of Science ®Google Scholar
• Hale JB, Reddy LA, Semrud-Clikeman M, et al. Executive impairment determines ADHD medications response: implications for academic achievement. J Learn Disabil 2011;44(2):196-212
   PubMed Web of Science ®Google Scholar
• Kubas HA, Backenson EM, Wilcox G, et al. The effects of methylphenidate on cognitive function in children with attention-deficit/hyperactivity disorder. Postgrad Med 2012;124(5):33-48
   PubMed Web of Science ®Google Scholar
• Advokat C. What are the cognitive effects of stimulant medications? Emphasis on adults with attention-deficit/hyperactivity disorder (ADHD). Neurosci Biobehav Rev 2010;34:1256-66
   PubMed Web of Science ®Google Scholar
• Volkow ND, Wang G, Fowler JS, et al. Evidence that methylphenidate enhances the saliency of a mathematical task by increasing dopamine in the human brain. Am J Psychiatry 2004;161:1173-80
   PubMed Web of Science ®Google Scholar
• Volkow ND, Wang GJ, Kollins SH, et al. Evaluating dopamine reward pathway in ADH: clinical implications. JAMA 2009;302(10):1084-91
   PubMed Web of Science ®Google Scholar
• Shiels K, Hawk LW Jr, Reynolds B, et al. Effects of methylphenidate on discounting of delayed rewards in attention deficit/hyperactivity disorder. Exp Clin Psychopharmacol 2009;17(5):291-301
   PubMed Web of Science ®Google Scholar
• Kosten T, Kosten A, McDougle C, et al. Gender differences in response to intranasal cocaine administration to humans. Biol Psychiatry 1996;39(2):147-8
   PubMed Web of Science ®Google Scholar
• Kuntsi J, Stevenson J. Psychological mechanisms in hyperactivity: II. The role of genetic factors. J Child Psychol Psychiatry 2001;42(2):211-19
   PubMed Web of Science ®Google Scholar
• Gillberg C, Melander H, von Knorring AL, et al. Long-term stimulant treatment of children with attention-deficit hyperactivity disorder symptoms: a randomized, double blind, placebo-controlled trial. Arch Gen Psychiatry 1997;54:857-64
   PubMed Web of Science ®Google Scholar
• MTA Cooperative Group. National Institute of Mental Health Multimodal Treatment Study of ADHD follow-up: 24-month outcomes of treatment strategies for attention-deficit/hyperactivity disorder. Pediatrics 2004;113:754-61
   PubMed Web of Science ®Google Scholar
• Molina BSG, Hinshaw SP, Swanson JM, et al. The MTA at 8 years: prospective follow-up of children treated for combined-type ADHD in a multisite study. J Am Acad Child Adolesc Psychiatry 2009;48:484-500
   PubMed Web of Science ®Google Scholar
• Wilens TE, Spencer TJ. The stimulants revisited. Child. Adolesc Psychiatr Clin N Am 2000;9:3:573-603. viii
   PubMed Web of Science ®Google Scholar
• McCarthy S, Asherson P, Coghill D, et al. Attention-deficit hyperactivity disorder: treatment discontinuation in adolescents and young adults. Br J Psychiatry 2009;194(3):273-7
   PubMed Web of Science ®Google Scholar
• Wilens TE, Decker MW. Neuronal nicotinic receptor agonists for the treatment of attention-deficit/hyperactivity disorder: focus on cognition. Biochem Pharmacol 2007;74:1212-23
   PubMed Web of Science ®Google Scholar
• Swanson J, Baler RD, Volkow ND. Understanding the effects of stimulant medications on cognition in individuals with attention-deficit hyperactivity disorder: a decade of progress. Neuropsychopharmacology 2011;36(1):207-26
   PubMed Web of Science ®Google Scholar
• Kimko HC, Cross JT, Abernethy DR. Pharmacokinetics and clinical effectiveness of methylphenidate. Clin Pharmacokinetics 1999;37(6):457-70
   PubMed Web of Science ®Google Scholar
• Daytrana prescribing information. Shire US Inc., Wayne, PA; 2010
   Google Scholar
• Swanson J, Volkow N. Pharmacokinetic and pharmacodynamic properties of methylphenidate in humans. In: Solanto, MV Arnsten, AF Castellanos, FX, editors. Stimulant drugs and ADHD: Basic and clinical neuroscience. Oxford University Press; New York; 2001. p. 259-82
   Google Scholar
• Brown RT, Amler RW, Freeman WS, et al. American Academy of Pediatrics Committee on Quality Improvement; American Academy of Pediatrics Subcommittee on Attention-Deficit/Hyperactivity Disorder. Treatment of attention-deficit/hyperactivity disorder: overview of the evidence. Pediatrics 2005;115(6):e749-57
   PubMedGoogle Scholar
• Swanson JM, Agler D, Fineberg E. University of California, Irvine. Laboratory school protocol for pharmacokinetic and pharmacodynamic studies. In: Greenhill, LL Osman, BB, editors. Ritalin: theory and practice. Mary Ann Liebert, New York; 2000. p. 405-30
   Google Scholar
• Swanson JM, Gupta S, Williams L, et al. Efficacy of a new pattern of delivery of methylphenidate for the treatment of ADHD: effects on activity level in the classroom and on the playground. J Am Acad Child Adolesc Psychiatry 2002;41:1306-14
   PubMed Web of Science ®Google Scholar
• Lopez F, Silva R, Pestreich L, Muniz R. Comparative efficacy of two once daily methylphenidate formulations (Ritalin® LATM and Concerta®) and placebo in children with attention deficit hyperactivity disorder across the school day. Pediatr Drugs 2003;5(8):545-55
   PubMedGoogle Scholar
• Markowitz JS, Straughn AB, Patrick KS. Advances in the pharmacotherapy of attention-deficit hyperactivity disorder: focus on methylphenidate formulations. Pharmacotherapy 2003;23(10):1281-99
   PubMed Web of Science ®Google Scholar
• Greenhill LL, Findling RL, Swanson JM. A double-blind, placebo-controlled study of modified-release methylphenidate in children with attention-deficit/hyperactivity disorder. Pediatrics 2002;109(3):E39
   PubMed Web of Science ®Google Scholar
• Findling RL, Quinn D, Hatch SJ, et al. Comparison of the clinical efficacy of twice-daily ritalin and once-daily equasym XL with placebo in children with attention deficit/hyperactivity disorder. Eur Child Adolesc Psychiatry 2006;15:450-9
   PubMed Web of Science ®Google Scholar
• Döpfner M, Banaschewski T, Schmidt J, et al. Langzeitwirksames Methylphenidat bei Kindern mit Aufmerksamkeitsdefizit-Hyperaktivitätsstörungen - Eine multizentrische Studie. Nervenheilkunde 2003;22:85-92
   Google Scholar
• Rösler M, Fischer R, Ammer R, et al. A randomised, placebo-controlled, 24-week, study of low dose extended-release methylphenidate in adults with attention-deficit/hyperactivity disorder. Eur Arch Psychiatry Clin Neurosci 2009;259:120-9
   PubMed Web of Science ®Google Scholar
• Döpfner M, Gerber WD, Banaschewski T, et al. Comparative efficacy of once-a-day extended-release methylphenidate, two-times-daily immediate-release methylphenidate, and placebo in a laboratory school setting. Eur Child Adolesc Psychiatry 2004;13:I93-101
   PubMed Web of Science ®Google Scholar
• Biederman J, Quinn D, Weiss M, et al. Efficacy and safety of Ritalin LA, a new, once daily, extended-release dosage form of methylphenidate, in children with attention deficit hyperactivity disorder. Paediatr Drugs 2003;5(12):833-41
   PubMedGoogle Scholar
• Lyseng-Williamson KA, Keating GM. Extended-release methylphenidate (Ritalin LA). Drugs 2002;62(15):2251-9
   PubMed Web of Science ®Google Scholar
• Moen MD, Keam SJ. Dexmethylphenidate extended release: a review of its use in the treatment of attention-deficit hyperactivity disorder. CNS Drugs 2009;23(12):1057-83
   PubMed Web of Science ®Google Scholar
• Swanson JM, Wigal SB, Wigal T, et al. A comparison of once-daily extended-release methylphenidate formulations in children with attention-deficit/hyperactivity disorder in the laboratory school (The COMACS Study). Pediatrics 2004;1113(3 pt 1):e206-16
   Google Scholar
• Muniz R, Brams M, Mao A, et al. Efficacy and safety of extended-release dexmethylphenidate compared with d, l-methylphenidate and placebo in the treatment of children with attention deficit hyperactivity disorder: a 12-hour laboratory classroom study. J Child Adolesc Psychopharmacol 2008;18(3):248-56
   PubMed Web of Science ®Google Scholar
• Silva R, Muniz R, McCague K, et al. Treatment of children with attention-deficit/hyperactivity disorer: results of a randomized, multicenter, double-blind, crossover study of extended-release dexmethylphenidate and d, l-methylphenidate and placebo in a laboratory classroom setting. Psychopharmacol Bull 2008;41(1):19-33
   PubMed Web of Science ®Google Scholar
• Moen MD, Keam SJ. Dexmethylphenidate extended release: a review of its use in the treatment of attention-deficit hyperactivity disorder. CNS Drugs 2009;23(12):1057-83
   PubMed Web of Science ®Google Scholar
• McGough JJ, Wigal SB, Abikoff H, et al. A randomized, double-blind, placebo-controlled, laboratory classroom assessment of methylphenidate transderma system in children with ADHD. J Atten Disord 2006;9(3):476-85
   PubMedGoogle Scholar
• Döpfner M, Görtz-Dorten A, Breuer D, Rothenberger A. An observational study of once-daily modified-release methylphenidate in ADHD: effectiveness on symptoms and impairment, and safety. Eur Child Adolesc Psychiatry 2011;20(suppl 2):243-55
   Google Scholar
• Lopez F, Silva R, Pestreich L, Muniz R. Comparative efficacy of two once daily methylphenidate formulations (Ritalin LA and Concerta) and placebo in children with attention deficit hyperactivity disorder across the school day. Paediatr Drugs 2003;5(8):545-55
   PubMedGoogle Scholar
• Bezchlibnyk-Butler K, Virani AS. Clinical Handbook of psychotropic drugs for children and adolescents. Hogrefe-Huber; Göttingen: 2007
   Google Scholar
• Grob CS, Coyle JT. Suspected adverse methylphenidate-imipramine interactions in children. J Dev Behav Pediatr 1986;7:265-7
   PubMed Web of Science ®Google Scholar
• Benjamin E, Salek S. Stimulant – atypical antipsychotic interaction and acute dystonia. J Am Acad Child Adolesc Psychiatry 2005;44:510-12
   PubMed Web of Science ®Google Scholar
• Conner DF. Stimulants and neuroleptic withdrawal dyskinesia. J Am Acids Child Adolesc Psychiatry 1998;37:247-8
   PubMed Web of Science ®Google Scholar
• Waes van V, Beverley J, Marinelli M, Steiner H. Selective serotonin reuptake inhibitor antidepressants potentiate methylphenidate (Ritalin)-induced gene regulation in the adolescent striatum. Eur J Neurosci 2010;32(3):435-47
   PubMed Web of Science ®Google Scholar
• Parisi P, Bruni O, Pia Villa M, et al. The relationship between sleep and epilepsy: the effect on cognitive functioning in children. Dev Med Child Neurol 2010;52(9):805-10
   PubMed Web of Science ®Google Scholar
• Behar D, Schaller J, Spreat S. Extreme reduction of methylphenidate levels by carbamazepine. J Am Acad Child Adolesc Psychiatry 1998;37(11):1128-9
   PubMed Web of Science ®Google Scholar
• Schaller JL, Behar D. Carbamazepine and methylphenidate in ADHD. J Am Acad Child Adolesc Psychiatry 1999;38(2):112-13
   PubMed Web of Science ®Google Scholar
• Markowitz JS, Patrick KS. Pharmacokinetic and pharmacodynamic drug interactions in the treatment of attention-deficit hyperactivity disorder. Clin Pharmacokinet 2001;40:753-72
   PubMed Web of Science ®Google Scholar
• Agarwal V, Sitholey P. Combination of atomoxetine and methylphenidate in attention deficit/hyperactivity disorder: a case report. J Can Acad Child Adolesc Psychiatry 2008;17:160
   PubMedGoogle Scholar
• Hammerness P, Georgiopoulos A, Doyle RL, et al. An open study of adjunct OROS-methylphenidate in children who are atomoxetine partial responders: II. Tolerability and pharmacokinetics. J Child Adolesc Psychopharmacol 2009;19:493-9
   PubMed Web of Science ®Google Scholar
• Zhu H, Patrick KS, Markowitz JS. Enantiospecific determination of dl-methylphenidate and dl-ethylphenidate in plasma by liquid chromarography-tandem mass spectrometry: application to human ethanol interactions. J Chromatogr B analyt Technol Biomed Life Sci 2011;879:783-8
   PubMed Web of Science ®Google Scholar
• Gevensleben H, Kleemeyer M, Rothenberger LG, et al. Neurofeedback in ADHD: further pieces of the puzzle. Brain Topogr 2013. [ Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Arnold LE. Methylphenidate vs. amphetamine: comparative review. J Attention Disord 2000;3(4):200-11
   Google Scholar
• Charach A, Gajaria A, Skyba A, Chen S. Documenting adherence to psychostimulants in children with ADHD. J Can Acad Child Adolesc Psychiatry 2008;17(3):131-6
   PubMedGoogle Scholar
• Owens JS, Hoza B. The role of inattention and hyperactivity/impulsivity in the positive illusory bias. J Consult Clin Psychol 2003;71(4):680-91
   PubMed Web of Science ®Google Scholar
• Stuber ML, Shemesh E, Seacord D, et al. Evaluating non-adherence to immunosuppressant medications in pediatric liver transplant recipients. Pediatr Transplant 2008;12(3):284-8
   PubMed Web of Science ®Google Scholar
• Setlik J, Bond GR, Ho M. Adolescent prescription ADHD medication abuse is rising along with prescriptions for these medications. Pediatrics 2009;124(3):875-80
   PubMed Web of Science ®Google Scholar
• Barbaresi WJ, Colligan RC, Weaver AL, et al. Mortality, ADHD, and Psychosocial Adversity in Adults With Childhood ADHD: a prospective study. Pediatrics 2013;131(4):637-44
   Google Scholar